Monica Morrow joins Memorial Sloan-Kettering Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

NEW YORK-Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

“We are very fortunate that Dr. Morrow, one of the country’s preeminent breast cancer surgeons, has joined our staff,” said Peter Scardino, MD, chair of the Department of Surgery. “Dr. Morrow is a superb physician, a distinguished spokesperson for breast cancer, and brings years of experience in surgical oncology to her new role.”

For more than 20 years, Dr. Morrow has been a leader in the treatment and prevention of breast cancer. After completing her surgical oncology training at MSKCC, she led the University of Chicago Hospital and Northwestern Memorial Hospital’s clinical breast programs. She served as co-principal investigator of Northwestern University’s Specialized Program of Research Excellence in Breast Cancer and, in 1996, received one of three inaugural grants from the Department of Defense Center for Excellence to increase access to modern multidisciplinary breast cancer care.

Prior to her appointment at MSKCC, she was chairman of surgical oncology at Fox Chase Cancer Center where she held the G. Willing “Wing” Pepper Chair in Cancer Research.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content